BioSpace News Archive

From search engines to social media, algorithms are quickly becoming a part of everyday life, and companies like Bayer, MIT and others are using them to their advantage.

COVID-19 is much more than a respiratory illness, and many of its longer-term effects and secondary issues are often puzzling. For that and more research news, continue reading.

AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe and a positive clinical trial update.

There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.

Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd.’s Phase 2 clinical trial of Tollovir™.

Pressure BioSciences, Inc. today announced the Company’s participation in the June 30th Revolutionizing the Development of Plant-Based Food Products webinar, sponsored by FORCE Family Office.

Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that the company will participate in two Hanson Wade summits taking place in July in Boston.

scPharmaceuticals Inc. today announced that the Company is hosting a virtual investor event on Wednesday, July 13, at 10:00 AM EDT.

Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that data from the Company’s Phase 1 leg immobilization study of REN001 in healthy volunteers has been accepted for presentation at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022),